vs
BCB BANCORP INC（BCBP）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是BCB BANCORP INC的1.2倍（$30.3M vs $26.2M），BCB BANCORP INC净利率更高（-49.7% vs -221.3%，领先171.7%），REGENXBIO Inc.同比增速更快（43.0% vs 13.1%），BCB BANCORP INC自由现金流更多（$34.9M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 1.8%）
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BCBP vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.2倍
$26.2M
营收增速更快
RGNX
高出29.9%
13.1%
净利率更高
BCBP
高出171.7%
-221.3%
自由现金流更多
BCBP
多$87.7M
$-52.8M
两年增速更快
RGNX
近两年复合增速
1.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $26.2M | $30.3M |
| 净利润 | $-12.0M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -71.9% | -190.0% |
| 净利率 | -49.7% | -221.3% |
| 营收同比 | 13.1% | 43.0% |
| 净利润同比 | -467.6% | -31.2% |
| 每股收益（稀释后） | $-0.73 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCBPRGNX
| Q4 25 | $26.2M | $30.3M | ||
| Q3 25 | $26.5M | $29.7M | ||
| Q2 25 | $25.2M | $21.4M | ||
| Q1 25 | $23.8M | $89.0M | ||
| Q4 24 | $23.1M | $21.2M | ||
| Q3 24 | $26.2M | $24.2M | ||
| Q2 24 | $20.4M | $22.3M | ||
| Q1 24 | $25.3M | $15.6M |
净利润BCBPRGNX
| Q4 25 | $-12.0M | $-67.1M | ||
| Q3 25 | $4.3M | $-61.9M | ||
| Q2 25 | $3.6M | $-70.9M | ||
| Q1 25 | $-8.3M | $6.1M | ||
| Q4 24 | $3.3M | $-51.2M | ||
| Q3 24 | $6.7M | $-59.6M | ||
| Q2 24 | $2.8M | $-53.0M | ||
| Q1 24 | $5.9M | $-63.3M |
毛利率BCBPRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率BCBPRGNX
| Q4 25 | -71.9% | -190.0% | ||
| Q3 25 | 21.9% | -176.3% | ||
| Q2 25 | 19.9% | -296.3% | ||
| Q1 25 | -49.2% | 13.6% | ||
| Q4 24 | 19.9% | -242.1% | ||
| Q3 24 | 35.7% | -256.6% | ||
| Q2 24 | 19.5% | -251.3% | ||
| Q1 24 | 33.0% | -408.8% |
净利率BCBPRGNX
| Q4 25 | -49.7% | -221.3% | ||
| Q3 25 | 16.1% | -208.3% | ||
| Q2 25 | 14.2% | -331.8% | ||
| Q1 25 | -35.0% | 6.8% | ||
| Q4 24 | 14.1% | -241.3% | ||
| Q3 24 | 25.5% | -246.3% | ||
| Q2 24 | 13.8% | -237.7% | ||
| Q1 24 | 23.2% | -405.4% |
每股收益（稀释后）BCBPRGNX
| Q4 25 | $-0.73 | $-1.30 | ||
| Q3 25 | $0.22 | $-1.20 | ||
| Q2 25 | $0.18 | $-1.38 | ||
| Q1 25 | $-0.51 | $0.12 | ||
| Q4 24 | $0.17 | $-0.99 | ||
| Q3 24 | $0.36 | $-1.17 | ||
| Q2 24 | $0.14 | $-1.05 | ||
| Q1 24 | $0.32 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $304.3M | $102.7M |
| 总资产 | $3.3B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCBPRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益BCBPRGNX
| Q4 25 | $304.3M | $102.7M | ||
| Q3 25 | $318.5M | $161.5M | ||
| Q2 25 | $315.7M | $213.7M | ||
| Q1 25 | $314.7M | $274.2M | ||
| Q4 24 | $323.9M | $259.7M | ||
| Q3 24 | $328.1M | $301.4M | ||
| Q2 24 | $320.7M | $348.3M | ||
| Q1 24 | $320.1M | $390.7M |
总资产BCBPRGNX
| Q4 25 | $3.3B | $453.0M | ||
| Q3 25 | $3.4B | $525.2M | ||
| Q2 25 | $3.4B | $581.0M | ||
| Q1 25 | $3.5B | $490.9M | ||
| Q4 24 | $3.6B | $466.0M | ||
| Q3 24 | $3.6B | $519.1M | ||
| Q2 24 | $3.8B | $569.4M | ||
| Q1 24 | $3.8B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.9M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $34.9M | $-52.8M |
| 自由现金流率自由现金流/营收 | 133.3% | -174.0% |
| 资本支出强度资本支出/营收 | 4.0% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $58.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BCBPRGNX
| Q4 25 | $35.9M | $-52.3M | ||
| Q3 25 | $8.7M | $-56.0M | ||
| Q2 25 | $10.3M | $-49.3M | ||
| Q1 25 | $5.0M | $33.6M | ||
| Q4 24 | $67.7M | $-31.6M | ||
| Q3 24 | $43.5M | $-40.5M | ||
| Q2 24 | $8.1M | $-45.5M | ||
| Q1 24 | $8.3M | $-55.5M |
自由现金流BCBPRGNX
| Q4 25 | $34.9M | $-52.8M | ||
| Q3 25 | $8.5M | $-56.5M | ||
| Q2 25 | $10.2M | $-49.7M | ||
| Q1 25 | $4.7M | $32.6M | ||
| Q4 24 | $66.5M | $-32.7M | ||
| Q3 24 | $43.4M | $-40.9M | ||
| Q2 24 | $8.1M | $-46.0M | ||
| Q1 24 | $8.1M | $-56.0M |
自由现金流率BCBPRGNX
| Q4 25 | 133.3% | -174.0% | ||
| Q3 25 | 32.0% | -189.9% | ||
| Q2 25 | 40.4% | -232.8% | ||
| Q1 25 | 19.8% | 36.6% | ||
| Q4 24 | 287.5% | -154.2% | ||
| Q3 24 | 166.0% | -168.9% | ||
| Q2 24 | 39.6% | -206.2% | ||
| Q1 24 | 32.3% | -358.5% |
资本支出强度BCBPRGNX
| Q4 25 | 4.0% | 1.7% | ||
| Q3 25 | 1.1% | 1.7% | ||
| Q2 25 | 0.6% | 1.8% | ||
| Q1 25 | 1.2% | 1.2% | ||
| Q4 24 | 5.3% | 5.1% | ||
| Q3 24 | 0.3% | 1.3% | ||
| Q2 24 | 0.2% | 2.1% | ||
| Q1 24 | 0.6% | 3.6% |
现金转化率BCBPRGNX
| Q4 25 | — | — | ||
| Q3 25 | 2.05× | — | ||
| Q2 25 | 2.90× | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | 20.70× | — | ||
| Q3 24 | 6.53× | — | ||
| Q2 24 | 2.88× | — | ||
| Q1 24 | 1.41× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCBP
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
